- Thinly traded micro cap CTI BioPharma (NASDAQ:CTIC) perks up 4% premarket on light volume. The most recent news was a Seeking Alpha article published on Monday by Avisol Capital Partners pointing out that pacritinib may have potential in myelofibrosis (MF) patients who have platelet counts of 100K/uL or less, a subpopulation of MF patients where Incyte's Jakafi (ruxolitinib) doesn't work well because the dose is limited to 5 mg instead of 20 mg.